Reversal of docetaxel resistance with bevacizumab and thalidomide.
Yang-Min Ning, William D Figg, William L Dahut
Index: Clin. Genitourin. Cancer 7(2) , E37-8, (2009)
Full Text: HTML
Abstract
Taxane resistance is a common clinical problem in the treatment of many metastatic malignancies. Observational clues or evidence of overcoming such resistance is important for developing treatments that can extend taxane activity. We report a case of the reversal of docetaxel resistance with the addition of antiangiogenic agents bevacizumab and thalidomide to docetaxel and prednisone in a patient with metastatic castration-resistant prostate cancer after PSAWG progression on docetaxel and prednisone. The patient then responded for an additional 7 months. The addition of bevacizumab and thalidomide after progression on docetaxel/prednisone might reverse docetaxel resistance. These or other antiangiogenic agents for overcoming clinical taxane resistance are candidates for further study.
Related Compounds
Related Articles:
Losartan competitively inhibits CYP2C8-dependent paclitaxel metabolism in vitro.
2014-01-01
[Biol. Pharm. Bull. 37(9) , 1550-4, (2014)]
2008-05-01
[Eur. J. Cancer 44(7) , 912-20, (2008)]
2009-01-01
[Clin. Cancer Res. 15(1) , 238-46, (2009)]
2010-01-01
[Eur. J. Cancer 46 , 3022-36, (2010)]
Novel therapeutic strategies in development for prostate cancer.
2008-01-01
[Expert Opin. Investig. Drugs 17(1) , 13-22, (2008)]